Table 1.
Demographics and clinical parameters.
| GROUPS Number (n) | AGE Months (IQR) | GENDER F/M | ALT<41IU(IQR) | AST<52IU(IQR) | GGT<18IU(IQR) | IgG5-15 g/L (IQR) | Presence of Autoantibodies |
|---|---|---|---|---|---|---|---|
|
Group-1:
AIH NAIVE PATIENTS (7) |
103 (50-221) |
4/3 | 180 (61-1119) |
64 (26-697) |
49 (25-116) |
15.8 (10-17) |
Anti-ANA/SMA: 28.5% (2) Anti-LKM1/LC1: 57% (4) Seronegative: 14.3% (1) |
|
Group-2: AIH LONGTERM FOLLOW-UP
(9) |
192 (142.5-212) |
5/4 | 34 (32-50) |
38 (34-51) |
22 (13-29) |
13.7 (10.8-14.9) |
Anti-ANA/SMA: 89.9% (8) Anti-LKM1/LC1: 0% (0) Seronegative: 11.1% (1) |
|
Group-3: AISC
overlap (3) |
204 (177-213) |
1/2 | 34 (15-63) |
34.5 (18-51) |
51 (28-88) |
10.8 (7.7-14) |
Anti-ANA/SMA: 66% (2) pANCA: 100% (3) |
|
Group-4: HC
PBMC (7) |
91 (57-108) |
2/5 | 14 (13-15) |
25 (na) |
15 (na) |
9.56 (7.8-10.6) |
na |
|
Group-5: DILI
(3) |
144 (52-204) |
1/2 | 386 (15-1457) |
97 (15-122) |
179 (14-413) |
8.8 (7.6-9.6) |
0% |
|
Group-6: LT
(9) |
72 (24-102) |
5/4 | 41 (25-77) |
46 (37-67) |
25 (13-68) |
12.9 (8.1-15.4) |
na |
|
Group-7: HBL
(3) |
35 (26-174) |
2/1 | 32 (27-409 |
50 (50-290) |
24 (20-62) |
7.3 (4.9-13.9) |
na |
|
Group-8: HC DONOR
LIVER (8) |
412 (262-444) |
5/3 | 13 (11-23) |
17 (14-22) |
16 (13-24) |
na | na |
DILI, drug-induced liver injury; HBL, hepatoblastoma; PBMC, peripheral blood mononuclear cells; LT, liver transplanted patients; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpepdidase; IQR, interquartile range; IgG, immunoglobulin G; anti-ANA, anti-nuclear antibodies; anti-SMA, anti-smooth muscle antibody; anti-LKM1, anti liver kidney microsomal antibodies; anti-LC1, anti liver cytosol antibody; pANCA, perinuclear antineutrophil cytoplasmic antibodies; AIH, autoimmune hepatitis; AISC, autoimmune sclerosing cholangitis; na, not applicable.